Coeptis Therapeutics Holdings Inc COEP

NAS: COEP | ISIN: US19207A1088   3/05/2024
0,360 USD (-2,60%)
(-2,60%)   3/05/2024
Grafiek Coeptis Therapeutics Holdings Inc Grafiek Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc in het nieuws

2 mei 2024 · Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting · Persbericht

2 april 2024 · Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award · Persbericht

26 februari 2024 · Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK · Persbericht

7 februari 2024 · Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections · Persbericht

4 januari 2024 · Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 · Persbericht

4 december 2023 · Coeptis Therapeutics to Present at the Emerging Growth Conference · Persbericht

31 oktober 2023 · Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 · Persbericht

24 oktober 2023 · Coeptis Therapeutics Announces $2 Million Private Placement · Persbericht

11 oktober 2023 · Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology · Persbericht

9 oktober 2023 · Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies · Persbericht

Profiel Coeptis Therapeutics Holdings Inc

Werknemers: 5

Aandelen Coeptis Therapeutics Holdings Inc

Beurswaarde: 12,99 miljoen USD

Effecten: 36,09 miljoen

Beta: 0,20

Mijn selecties